```
  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:04:25 ON 08 FEB 2006

=> index biosci
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
       AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
       CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
       DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 17:04:38 ON 08 FEB 2006

70 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s Nod1
          1   FILE ADISINSIGHT
         18   FILE AGRICOLA
         12   FILE BIOENG
        130   FILE BIOSIS
         10   FILE BIOTECHABS
         10   FILE BIOTECHDS
         30   FILE BIOTECHNO
         38   FILE CABA
        127   FILE CAPLUS
          2   FILE CONFSCI
          1   FILE CROPU
          1   FILE DDFU
        227   FILE DGENE
          3   FILE DISSABS
          2   FILE DRUGU
          7   FILE EMBAL
         82   FILE EMBASE
         84   FILE ESBIOBASE
          4   FILE FEDRIP
  32 FILES SEARCHED...
         30   FILE GENBANK
         22   FILE IFIPAT
         18   FILE JICST-EPLUS
         54   FILE LIFESCI
         71   FILE MEDLINE
         42   FILE PASCAL
          2   FILE PROMT
        117   FILE SCISEARCH
         28   FILE TOXCENTER
         72   FILE USPATFULL
         15   FILE USPAT2
  66 FILES SEARCHED...
         13   FILE WPIDS
         13   FILE WPINDEX

  32 FILES HAVE ONE OR MORE ANSWERS,    70 FILES SEARCHED IN STNINDEX

L1    QUE NOD1

=> s l1 and ((muramyl (w) tripeptide or mtp)
UNMATCHED LEFT PARENTHESIS 'AND ((MURAMYL'
The number of right parentheses in a query must be equal to the
number of left parentheses.

=>  s l1 and ((muramyl (w) tripeptide or mtp))
          1   FILE BIOSIS
          1   FILE BIOTECHABS
          1   FILE BIOTECHDS
          2   FILE CAPLUS
          1   FILE DGENE
          1   FILE EMBASE
          1   FILE ESBIOBASE
  30 FILES SEARCHED...
          1   FILE IFIPAT
          2   FILE MEDLINE
          3   FILE SCISEARCH
          8   FILE USPATFULL
          2   FILE USPAT2
          1   FILE WPIDS
  68 FILES SEARCHED...
          1   FILE WPINDEX

  14 FILES HAVE ONE OR MORE ANSWERS,    70 FILES SEARCHED IN STNINDEX

L2    QUE L1 AND ((MURAMYL (W) TRIPEPTIDE OR MTP))

=> file hits
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     3.05       3.26

FILE 'USPATFULL' ENTERED AT 17:07:27 ON 08 FEB 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'SCISEARCH' ENTERED AT 17:07:27 ON 08 FEB 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 17:07:27 ON 08 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 17:07:27 ON 08 FEB 2006

FILE 'USPAT2' ENTERED AT 17:07:27 ON 08 FEB 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 17:07:27 ON 08 FEB 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 17:07:27 ON 08 FEB 2006
```

COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'DGENE' ENTERED AT 17:07:27 ON 08 FEB 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 17:07:27 ON 08 FEB 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 17:07:27 ON 08 FEB 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'IFIPAT' ENTERED AT 17:07:27 ON 08 FEB 2006
COPYRIGHT (C) 2006 IFI CLAIMS(R) Patent Services (IFI)

FILE 'WPIDS' ENTERED AT 17:07:27 ON 08 FEB 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s l2
L3 24 L2

=> dup rem l3
DUPLICATE IS NOT AVAILABLE IN 'DGENE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L3
L4 15 DUP REM L3 (9 DUPLICATES REMOVED)

=> d l4 bib ab 1-15

L4 ANSWER 1 OF 15 USPATFULL on STN
AN 2005:234109 USPATFULL
TI Human leucine-rich repeat containing protein expressed predominately in bone marrow, HLRRBM1
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES
Bol, David, Langhorne, PA, UNITED STATES
Hawken, Donald R., Lawrenceville, NJ, UNITED STATES
PI US 2005203048 A1 20050915
AI US 2005-107572 A1 20050415 (11)
RLI Division of Ser. No. US 2002-183770, filed on 27 Jun 2002, PENDING
Continuation-in-part of Ser. No. US 2001-28374, filed on 20 Dec 2001, ABANDONED
PRAI US 2000-257773P 20001222 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US
CLMN Number of Claims: 12
ECL Exemplary Claim: 1-13
DRWN 12 Drawing Page(s)
LN.CNT 12553
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding HLRRBM1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRBM1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly immune diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

L4 ANSWER 2 OF 15 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN
AN 2005:1093479 SCISEARCH
GA The Genuine Article (R) Number: 978VT
TI Selective recognition of synthetic lysine and meso-diaminopimelic acid-type peptidoglycan fragments by human peptidoglycan recognition proteins I alpha and S
AU Kumar S; Roychowdhury A; Ember B; Wang Q; Guan R J; Mariuzza R A (Reprint); Boons G J
CS Univ Georgia, Complex Carbohydrate Res Ctr, 315 Riverbend Rd, Athens, GA 30602 USA (Reprint); Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, WM Keck Lab Struct Biol, Rockville, MD 20850 USA
mariuzza@carb.nist.gov; gjboons@ccrc.uga.edu
CYA USA
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (4 NOV 2005) Vol. 280, No. 44, pp. 37005-37012.
ISSN: 0021-9258.
PB AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA.
DT Article; Journal
LA English
REC Reference Count: 45
ED Entered STN: 10 Nov 2005
Last Updated on STN: 10 Nov 2005
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
AB The interactions of a range of synthetic peptidoglycan derivatives with PGRP-I alpha and PGRP-S have been studied in real-time using surface plasmon resonance. A dissociation constant of K-D = 62 mu M was obtained for the interaction of peptidoglycan recognition protein (PGRP)-I alpha with the lysine-containing muramyl pentapeptide (compound 6). The normalized data for the lysine-containing muramyl tetra- (compound 5) and pentapeptide (compound 6) showed that these compounds have similar affinities, whereas a much lower affinity for ***muramyl*** ***tripeptide*** (compound 3) was measured. Similar affinities were obtained when the lysine moiety of the muramyl peptides was replaced by meso-diaminopimelic acid (DAP). Furthermore, the compounds that contained only a stem peptide (pentapeptide, compound 1) and (DAP-PP, compound 2) as well as muramyldipeptide (compound 3) exhibited no binding indicating that the muramyltripeptide (compound 4) is the smallest peptidoglycan fragment that can be recognized by PGRP-I alpha. Surprisingly, PGRP-S derived significantly higher affinities for the DAP-containing fragments to similar lysine-containing derivatives, and the following dissociation constants were measured: muramylpentapeptide-DAP, K-D = 104 nM; muramyltetrapeptide-DAP, 92.4 nM; and muramyltripeptide-DAP, 326 nM. The binding profiles were rationalized by using a recently reported x-ray crystal structure of PGRP-I alpha with the lysine-containing muramyltripeptide (4).

L4 ANSWER 3 OF 15 MEDLINE on STN
AN 2005565962 MEDLINE
DN PubMed ID: 16115863
TI The frameshift mutation in Nod2 results in unresponsiveness not only to Nod2- but also ***Nod1*** -activating peptidoglycan agonists.
AU Netea Mihai G; Ferwerda Gerben; de Jong Dirk J; Werts Catherine; Boneca Ivo G; Jehanno Muguette; Van Der Meer Jos W M; Mengin-Lecreulx Dominique; Sansonetti Philippe J; Philpott Dana J; Dharancy Sebastien; Girardin Stephen E
CS Department of Internal Medicine, Radboud University Nijmegen Medical Center, The Netherlands.
SO The Journal of biological chemistry, (2005 Oct 28) 280 (43) 35859-67. Electronic Publication: 2005-08-22. Journal code: 2985121R. ISSN: 0021-9258.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200601
ED Entered STN: 20051025
Last Updated on STN: 20060105
Entered Medline: 20060104
AB NOD2/CARD15 is the first characterized susceptibility gene in Crohn disease. The Nod2 1007fs (Nod2fs) frameshift mutation is the most prevalent in Crohn disease patients. Muramyl dipeptide from bacterial peptidoglycan is the minimal motif detected by Nod2 but not by Nod2fs. Here we investigated the response of human peripheral blood mononuclear cells (PBMCs) from Crohn disease patients not only to muramyl dipeptide but also to several other muramyl peptides. Most unexpectedly, we observed that patients homozygous for the Nod2fs mutation were totally unresponsive to MurNAc-L-Ala-D-Glu-meso-diaminopimelic acid (DAP) (M-Tri(DAP)), the specific agonist of ***Nod1*** , and to Gram-negative bacterial peptidoglycan. In contrast, PBMCs from a patient homozygous for the Nod2 R702W mutation, also associated with Crohn disease, displayed normal response to Gram-negative bacterial peptidoglycan. In addition, the blockage of the ***Nod1*** /M-Tri(DAP) pathway could be partially overcome by co-stimulation with the Toll-like receptors agonists lipoteichoic acid or lipopolysaccharide. Investigation into the mechanism of this finding revealed that Nod2fs did not act as a dominant-negative molecule for the ***Nod1*** /M-Tri(DAP) pathway, implying that the blockage is dependent upon the expression or activity of other factors. We demonstrated that PBMCs from Nod2fs patients express high levels of the peptidoglycan recognition protein S, a secreted protein known to interact with muramyl peptides. We proposed that through a scavenger function, peptidoglycan recognition protein S may dampen M-Tri(DAP)-dependent responses in Nod2fs patients. Together, our results identified a cross-talk between the ***Nod1*** and Nod2 pathways and suggested that down-regulation of ***Nod1*** /M-Tri(DAP) pathway may be associated with Crohn disease.

L4 ANSWER 4 OF 15 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 1
AN 2005:1154463 SCISEARCH
GA The Genuine Article (R) Number: 983LD
TI Synthesis and proinflammatory properties of muramyl tripeptides containing lysine and diaminopimelic acid moieties
AU Roychowdhury A; Wolfert M A; Boons G J (Reprint)
CS Univ Georgia, Complex Carbohydrated Res Ctr, 315 Riverbend Rd, Athens, GA 30602 USA (Reprint); Univ Georgia, Complex Carbohydrated Res Ctr, Athens, GA 30602 USA
gjboons@ccrc.uga.edu
CYA USA
SO CHEMBIOCHEM, (NOV 2005) Vol. 6, No. 11, pp. 2088-2097. ISSN: 1439-4227.
PB WILEY-V C H VERLAG GMBH, PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY.
DT Article; Journal
LA English
REC Reference Count: 58
ED Entered STN: 1 Dec 2005
Last Updated on STN: 1 Dec 2005
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
AB The unusual amino acid diaminopimelic acid (DAP) was prepared by cross metathesis of appropriately protected vinyl glycine and allyl glycine derivatives. Catalytic hydrogenation of the cross-coupling product resulted in reduction of the double bond and the removal of protecting groups. The resulting compounds were appropriately protected for the polymer-supported and solution-phase synthesis of muramyl tripeptides 2 and 3, which differ in the amidation of the a-carboxylic acids of the isoglutamine and DAP moieties. Muramyl dipeptide (1, MDP), the DAP-containing ***muramyl*** ***tripeptide*** 3, and the lysine-containing muramyl tripeptides 4 and 5 induced TNF-alpha gene expression without TNF-a protein production in a human monocytic cell line. The observed block in translation could be removed by co-incubation with LPS, resulting in an apparent synergistic effect. Compound 2 did not induce TNF-alpha gene expression, neither did it exhibit a synergistic effect with LPS; this indicates that amidation of the a-carboxylic acids of the isoglutamine and DAP moieties results in a loss of biological activity. It is proposed that amidation of a-carboxylic acids is a strategy that may be used by pathogens to avoid detection by the innate immune system. Furthermore, the pattern recognition receptors ***Nod1*** and Nod2 have been implicated in the possible induction of a synergistic effect of muropeptides with LPS.

L4 ANSWER 5 OF 15 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN
AN 2005:849129 SCISEARCH
GA The Genuine Article (R) Number: 955OH
TI NOD-LRR proteins: Role in host-microbial interactions and inflammatory disease
AU Inohara N (Reprint); Chamaillard M; McDonald C; Nunez G
CS Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA (Reprint); Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
ino@umich.edu; mathiasc@umich.edu; mcdonalc@umich.edu; bclx@umich.edu
CYA USA
SO ANNUAL REVIEW OF BIOCHEMISTRY, (2005) Vol. 74, pp. 355-383. ISSN: 0066-4154.
PB ANNUAL REVIEWS, 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 USA.
DT General Review; Journal
LA English
REC Reference Count: 166
ED Entered STN: 1 Sep 2005
Last Updated on STN: 1 Sep 2005
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Nods are cytosolic proteins that contain a nucleotide-binding oligomerization domain (NOD). These proteins include key regulators of apoptosis and pathogen resistance in mammals and plants. A large number of Nods contain leucine-rich repeats (LRRs), hence referred to as NOD-LRR proteins. Genetic variation in several NOD-LRR proteins, including human Nod2, Cryopyrin, and CIITA, as well as mouse Naip5, is associated with inflammatory disease or increased susceptibility to microbial infections. ***Nod1*** , Nod2, Cryopyrin, and Ipaf have been implicated in protective immune responses against pathogens. Together with Toll-like receptors, ***Nod1*** and Nod2 appear to play important roles in innate and acquired immunity as sensors of bacterial components. Specifically, Nod 1 and Nod2 participate in the signaling events triggered by host recognition of specific motifs in bacterial peptidoglycan and, upon activation, induce the production of proinflammatory mediators. Naip5 is involved in host resistance to Legionella pneumophila through cell autonomous mechanisms, whereas CIITA plays a critical role in antigen presentation and development of antigen-specific T lymphocytes. Thus, NOD-LRR proteins appear to be involved in a diverse array of processes required for host immune reactions against pathogens.

L4 ANSWER 6 OF 15 USPATFULL on STN DUPLICATE 2
AN 2004:299866 USPATFULL
TI Method for modulating ***Nod1*** activity, use of a ***MTP*** related molecule for modulating ***Nod1*** activity, and therapeutic applications thereof
IN Girardin, Stephen, Vincennes, FRANCE
Philpott, Dana, Vincennes, FRANCE
Sansonetti, Philippe, Paris, FRANCE
Boneca, Ivo, Vltry Sur Seine, FRANCE
PI US 2004235735 A1 20041125
AI US 2004-808735 A1 20040325 (10)
PRAI US 2003-457572P 20030327 (60)
DT Utility
FS APPLICATION
LREP Finnegan Henderson Farabow Garrett & Dunner, Suite 700, 1300 I Street, N.W., Washington, DC, 20005
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 26 Drawing Page(s)
LN.CNT 1355
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for modulating Nod 1 activity wherein said method comprises the steps of providing cells expressing a functional Nod 1; and bringing said cells into contact with a molecule related to compositions comprising a molecule related to ***MTP*** and use of a molecule related to ***MTP*** for modulating inflammation and/or apoptosis

L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 3
AN 2004:824122 CAPLUS
DN 141:325709
TI A method for modulating ***Nod1*** activity, use of a ***muramyl*** ***tripeptide*** (***MTP***)-related molecule for modulating ***Nod1*** activity, and therapeutic applications thereof
IN Sansonetti, Philippe; Girardin, Stephen; Philpott, Dana; Boneca, Ivo
PA Institut Pasteur, Fr.; Institut National de la Sante et de la Recherche Medicale
SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004086039	A2	20041007	WO 2004-IB1318	20040329
	WO 2004086039	C1	20041104		
	WO 2004086039	A3	20050113		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004235735	A1	20041125	US 2004-808735	20040325
	CA 2520662	AA	20041007	CA 2004-2520662	20040329
	EP 1613958	A2	20060111	EP 2004-724084	20040329
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
PRAI	US 2003-457572P	P	20030327		
	WO 2004-IB1318	W	20040329		

AB The invention discloses a method for modulating ***Nod1*** activity which comprises providing cells expressing a functional ***Nod1*** and bringing the cells into contact with a mol. related to ***MTP*** . The invention also discusses the use of a mol. related to ***MTP*** for modulating inflammation and /or apoptosis. The invention further discloses the methods for e.g. detection of peptidoglycan from a Gram-neg. bacteria in a sample.

L4 ANSWER 8 OF 15 USPATFULL on STN
AN 2004:334808 USPATFULL
TI Novel human leucine-rich repeat containing protein expressed predominately in small intestine, HLRRSI1
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES
PI US 2004265890 A1 20041230
AI US 2004-882761 A1 20040701 (10)
RLI Division of Ser. No. US 2001-29347, filed on 20 Dec 2001, PENDING
PRAI US 2000-257774P 20001222 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 14389
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding HLRRSI1

polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRSI1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly gastrointestinal diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

L4 ANSWER 9 OF 15 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
AN 2005:322248 BIOSIS
DN PREV200510112030
TI Host recognition of peptidoglycan by intracellular receptor ***Nod1*** and Nod2, investigation with synthetic partial structures.
AU Kawasaki, Akiko [Reprint Author]; Inamura, Seiichi; Shimoyama, Atsushi; Inohara, Naohiro; Nunez, Gabriel; Fujimoto, Yukari; Fukase, Koichi; Kusumoto, Shoichi
CS Osaka Univ, Grad Sch Sci, Dept Chem, Osaka 5600043, Japan
SO Glycobiology, (NOV 2004) Vol. 14, No. 11, pp. 1199-1200. Meeting Info.: Joint Meeting of the Society-for-Glycobiology/Japanese-Society-for-Carbohydrate-Research. Honolulu, HI, USA. November 17 -20, 2004. Soc Gylcobiol; Japanese Soc Carbohydrate Res. ISSN: 0959-6658.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 25 Aug 2005
Last Updated on STN: 25 Aug 2005

L4 ANSWER 10 OF 15 USPATFULL on STN DUPLICATE 4
AN 2003:257761 USPATFULL
TI Novel human leucine-rich repeat containing protein expressed predominately in bone marrow, HLRRBM1
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabe, Hightstown, NJ, UNITED STATES
PI US 2003180812 A1 20030925
US 6949363 B2 20050927
AI US 2002-183770 A1 20020627 (10)
RLI Continuation-in-part of Ser. No. US 2001-28374, filed on 20 Dec 2001, PENDING
PRAI US 2000-257773P 20001222 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 12615
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding HLRRBM1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRBM1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly immune diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

L4 ANSWER 11 OF 15 USPATFULL on STN DUPLICATE 5
AN 2003:23722 USPATFULL
TI Novel human leucine-rich repeat containing protein expressed predominately in small intestine, HLRRSI1
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES
PI US 2003017562 A1 20030123
US 6858407 B2 20050222
AI US 2001-29347 A1 20011220 (10)
PRAI US 2000-257774P 20001222 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 14217
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding HLRRSI1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRSI1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly gastrointestinal diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

L4 ANSWER 12 OF 15 USPATFULL on STN
AN 2003:265252 USPATFULL
TI Novel human leucine-rich repeat domain containing protein, HLLRCR-1
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabriel, Hightstown, NJ, UNITED STATES
PI US 2003186267 A1 20031002
AI US 2002-271078 A1 20021011 (10)
PRAI US 2001-328478P 20011011 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 14036
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding HLLRCR-1 polypeptides, fragments and homologues thereof. Also provided are

vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLLRCR-1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly nervous system diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

L4 ANSWER 13 OF 15 USPATFULL on STN
AN 2003:207348 USPATFULL
TI Novel human leucine-rich repeat containing protein expressed predominately in bone marrow, HLRRBM1
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabe, Hightstown, NJ, UNITED STATES
PI US 2003143706 A1 20030731
AI US 2001-28374 A1 20011220 (10)
PRAI US 2000-257773P 20001222 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 13850
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding HLRRBM1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRBM1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly immune diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

L4 ANSWER 14 OF 15 USPATFULL on STN
AN 2003:127127 USPATFULL
TI Novel human leucine-rich repeat containing protein expressed predominately in nervous system tissues, HLRRNS1
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabe, Hightstown, NJ, UNITED STATES
PI US 2003087340 A1 20030508
AI US 2001-28392 A1 20011220 (10)
PRAI US 2001-259479P 20010103 (60)
US 2001-260616P 20010109 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 15374
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding HLRRNS1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRNS1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly nervous system diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

L4 ANSWER 15 OF 15 DGENE COPYRIGHT 2006 The Thomson Corp on STN
AN ADT61139 peptide DGENE
TI Modulating ***Nod1*** activity, involves expressing functional ***Nod1*** in eukaryotic cell and contacting cell with molecule related to ***muramyl*** ***tripeptide*** .
IN Sansonetti P; Girardin S; Philpott D; Boneca I
PA (INSP) INST PASTEUR.
(INRM) INSERM INST NAT SANTE & RECH MEDICALE.
PI WO 2004086039 A2 20041007 43
AI WO 2004-IB1318 20040329
PRAI US 2003-457572P 20030327
DT Patent
LA English
OS 2004-737364 [72]
DESC ***Nod1*** activity modulation-related peptide.
AB This invention relates to a novel method of modulating ***Nod1*** activity, which comprises expressing a functional ***Nod1*** in a eukaryotic cell, and contacting the cell with a molecule related to ***muramyl*** ***tripeptide*** (***MTP***). The invention may be useful for the production of compounds with an antiinflammatory, cytostatic or antibacterial activity acting as agonists or antagonists of ***Nod1*** protein or a vaccine. The method is useful for modulating ***Nod1*** activity and for preventing or treating a Gram-negative bacteria infection. The invention is also useful for increasing in vivo inflammation and/or apoptosis, for enhancing the immune response of a host or as an adjuvant agent in eukaryotes. The present sequence is that of a peptide which was used in the exemplification of the method of the invention.

=> d his

(FILE 'HOME' ENTERED AT 17:04:25 ON 08 FEB 2006)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 17:04:38 ON 08 FEB 2006
SEA NOD1

1 FILE ADISINSIGHT
18 FILE AGRICOLA
12 FILE BIOENG
130 FILE BIOSIS

```
            10   FILE BIOTECHABS
            10   FILE BIOTECHDS
            30   FILE BIOTECHNO
            38   FILE CABA
           127   FILE CAPLUS
             2   FILE CONFSCI
             1   FILE CROPU
             1   FILE DDFU
           227   FILE DGENE
             3   FILE DISSABS
             2   FILE DRUGU
             7   FILE EMBAL
            82   FILE EMBASE
            84   FILE ESBIOBASE
             4   FILE FEDRIP
            30   FILE GENBANK
            22   FILE IFIPAT
            18   FILE JICST-EPLUS
            54   FILE LIFESCI
            71   FILE MEDLINE
            42   FILE PASCAL
             2   FILE PROMT
           117   FILE SCISEARCH
            28   FILE TOXCENTER
            72   FILE USPATFULL
            15   FILE USPAT2
            13   FILE WPIDS
            13   FILE WPINDEX
L1           QUE NOD1
             ---------
             SEA L1 AND ((MURAMYL (W) TRIPEPTIDE OR MTP))
             ---------
             1   FILE BIOSIS
             1   FILE BIOTECHABS
             1   FILE BIOTECHDS
             2   FILE CAPLUS
             1   FILE DGENE
             1   FILE EMBASE
             1   FILE ESBIOBASE
             1   FILE IFIPAT
             2   FILE MEDLINE
             3   FILE SCISEARCH
             8   FILE USPATFULL
             2   FILE USPAT2
             1   FILE WPIDS
             1   FILE WPINDEX
L2           QUE L1 AND ((MURAMYL (W) TRIPEPTIDE OR MTP))
             ---------

    FILE 'USPATFULL, SCISEARCH, CAPLUS, MEDLINE, USPAT2, BIOSIS, BIOTECHDS,
    DGENE, EMBASE, ESBIOBASE, IFIPAT, WPIDS' ENTERED AT 17:07:27 ON 08 FEB
    2006
L3          24 S L2
L4          15 DUP REM L3 (9 DUPLICATES REMOVED)

=> log h
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              71.76      75.02

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                              -0.75      -0.75

 SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 17:08:12 ON 08 FEB 2006

* * * * * * * * * * * * * * STN  Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:54:01 ON 16 FEB 2006

=> index biosci
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               0.21       0.21

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
      AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
      CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
      DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 14:54:10 ON 16 FEB 2006

70 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s muramyl tripeptide
           51   FILE ADISCTI
            1   FILE ADISINSIGHT
            2   FILE ADISNEWS
            2   FILE AGRICOLA
            1   FILE ANABSTR
           14   FILE BIOENG
  9 FILES SEARCHED...
          223   FILE BIOSIS
            6   FILE BIOTECHABS
            6   FILE BIOTECHDS
           90   FILE BIOTECHNO
           17   FILE CABA
          183   FILE CAPLUS
            3   FILE CIN
            9   FILE CONFSCI
 19 FILES SEARCHED...
            2   FILE DDFB
          159   FILE DDFU
            1   FILE DGENE
            5   FILE DISSABS
            2   FILE DRUGB
          173   FILE DRUGU
 27 FILES SEARCHED...
          220   FILE EMBASE
           38   FILE ESBIOBASE
 35 FILES SEARCHED...
```

```
        25   FILE IFIPAT
         5   FILE IMSDRUGNEWS
         5   FILE IMSRESEARCH
         3   FILE JICST-EPLUS
        59   FILE LIFESCI
       219   FILE MEDLINE
         8   FILE NTIS
        99   FILE PASCAL
  50 FILES SEARCHED...
         3   FILE PHAR
         1   FILE PHARMAML
        12   FILE PHIN
        44   FILE PROMT
         1   FILE PROUSDDR
  58 FILES SEARCHED...
       208   FILE SCISEARCH
         1   FILE SYNTHLINE
       213   FILE TOXCENTER
       375   FILE USPATFULL
        37   FILE USPAT2
  65 FILES SEARCHED...
        29   FILE VETU
         1   FILE WATER
        20   FILE WPIDS
  69 FILES SEARCHED...
        20   FILE WPINDEX

  44 FILES HAVE ONE OR MORE ANSWERS,   70 FILES SEARCHED IN STNINDEX

L1   QUE MURAMYL TRIPEPTIDE

=> d rank l1
'FULL' IS NOT VALID IN THE CURRENT FILE
This option is not valid in the current file.  Enter the command
without the option at the arrow prompt (=>).  Or, first enter the
file in which the saved item created.  Then enter the command and
option at an arrow prompt in the file.

=> d rank
F1          375   USPATFULL
F2          223   BIOSIS
F3          220   EMBASE
F4          219   MEDLINE
F5          213   TOXCENTER
F6          208   SCISEARCH
F7          183   CAPLUS
F8          173   DRUGU
F9          159   DDFU
F10          99   PASCAL
F11          90   BIOTECHNO
F12          59   LIFESCI
F13          51   ADISCTI
F14          44   PROMT
F15          38   ESBIOBASE
F16          37   USPAT2
F17          29   VETU
F18          25   IFIPAT
F19          20   WPIDS
F20          20   WPINDEX
F21          17   CABA
F22          14   BIOENG
F23          12   PHIN
F24           9   CONFSCI
F25           8   NTIS
F26           6   BIOTECHABS
F27           6   BIOTECHDS
F28           5   DISSABS
F29           5   IMSDRUGNEWS
F30           5   IMSRESEARCH
F31           3   CIN
F32           3   JICST-EPLUS
F33           3   PHAR
F34           2   ADISNEWS
F35           2   AGRICOLA
F36           2   DDFB
F37           2   DRUGB
F38           1   ADISINSIGHT
F39           1   ANABSTR
F40           1   DGENE
F41           1   PHARMAML
F42           1   PROUSDDR
F43           1   SYNTHLINE
F44           1   WATER

=> file f1-f22
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               4.27       4.48

FILE 'USPATFULL' ENTERED AT 14:58:08 ON 16 FEB 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 14:58:08 ON 16 FEB 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 14:58:08 ON 16 FEB 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 14:58:08 ON 16 FEB 2006

FILE 'TOXCENTER' ENTERED AT 14:58:08 ON 16 FEB 2006
COPYRIGHT (C) 2006 ACS

FILE 'SCISEARCH' ENTERED AT 14:58:08 ON 16 FEB 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 14:58:08 ON 16 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DRUGU' ENTERED AT 14:58:08 ON 16 FEB 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION
```

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'PASCAL' ENTERED AT 14:58:08 ON 16 FEB 2006
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2006 INIST-CNRS. All rights reserved.

FILE 'BIOTECHNO' ENTERED AT 14:58:08 ON 16 FEB 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'LIFESCI' ENTERED AT 14:58:08 ON 16 FEB 2006
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'ADISCTI' ENTERED AT 14:58:08 ON 16 FEB 2006
COPYRIGHT (C) 2006 Adis Data Information BV

FILE 'PROMT' ENTERED AT 14:58:08 ON 16 FEB 2006
COPYRIGHT (C) 2006 Gale Group. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 14:58:08 ON 16 FEB 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'USPAT2' ENTERED AT 14:58:08 ON 16 FEB 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETU' ENTERED AT 14:58:08 ON 16 FEB 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'IFIPAT' ENTERED AT 14:58:08 ON 16 FEB 2006
COPYRIGHT (C) 2006 IFI CLAIMS(R) Patent Services (IFI)

FILE 'WPIDS' ENTERED AT 14:58:08 ON 16 FEB 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'CABA' ENTERED AT 14:58:08 ON 16 FEB 2006
COPYRIGHT (C) 2006 CAB INTERNATIONAL (CABI)

FILE 'BIOENG' ENTERED AT 14:58:08 ON 16 FEB 2006
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

=> s l1 (p) (nod1 or card4)
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L1 (P) '
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L1 (P) '
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L1 (P) '
  14 FILES SEARCHED...
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L1 (P) '
L2   9 L1 (P) (NOD1 OR CARD4)

=> dup rem l2
PROCESSING COMPLETED FOR L2
L3   4 DUP REM L2 (5 DUPLICATES REMOVED)

=> d l3 bib ab 1-4

L3 ANSWER 1 OF 4 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN DUPLICATE 1
AN 2005508211 EMBASE
TI Synthesis and proinflammatory properties of muramyl tripeptides containing lysine and diaminopimelic acid moieties.
AU Roychowdhury A.; Wolfert M.A.; Boons G.-J.
CS Prof. G.-J. Boons, Complex Carbohydrate Research Center, University of Georgia, 315 Riverbend Road, Athens, GA 30602, United States. gjboons@ccrc.uga.edu
SO ChemBioChem, (2005) Vol. 6, No. 11, pp. 2088-2097. .
    Refs: 58
    ISSN: 1439-4227 CODEN: CBCHFX
CY Germany
DT Journal; Article
FS 004 Microbiology
    030 Pharmacology
    037 Drug Literature Index
LA English
SL English
ED Entered STN: 20051201
    Last Updated on STN: 20051201
AB The unusual amino acid diaminopimelic acid (DAP) was prepared by cross metathesis of appropriately protected vinyl glycine and allyl glycine derivatives. Catalytic hydrogenation of the cross-coupling product resulted in reduction of the double bond and the removal of protecting groups. The resulting compounds were appropriately protected for the polymer-supported and solution-phase synthesis of muramyl tripeptides 2 and 3, which differ in the amidation of the .alpha.-carboxylic acids of the isoglutamine and DAP moieties. Muramyl dipeptide (1, MDP), the DAP-containing ***muramyl*** ***tripeptide*** 3, and the lysine-containing muramyl tripeptides 4 and 5 induced TNF-.alpha. gene expression without TNF-.alpha. protein production in a human monocytic cell line. The observed block in translation could be removed by co-incubation with LPS, resulting in an apparent synergistic effect. Compound 2 did not induce TNF-.alpha. gene expression, neither did it exhibit a synergistic effect with LPS; this indicates that amidation of the .alpha.-carboxylic acids of the isoglutamine and DAP moieties results in a loss of biological activity. It is proposed that amidation of .alpha.-carboxylic acids is a strategy that may be used by pathogens to avoid detection by the innate immune system. Furthermore, the pattern recognition receptors ***Nod1*** and Nod2 have been implicated in the possible induction of a synergistic effect of muropeptides with LPS. .COPYRGT. 2005 Wiley-VCH Verlag GmbH & Co. KGaA.

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2
AN 2004:824122 CAPLUS
DN 141:325709
TI A method for modulating ***Nod1*** activity, use of a ***muramyl*** ***tripeptide*** (MTP)-related molecule for modulating ***Nod1*** activity, and therapeutic applications thereof
IN Sansonetti, Philippe; Girardin, Stephen; Philpott, Dana; Boneca, Ivo
PA Institut Pasteur, Fr.; Institut National de la Sante et de la Recherche

Medicale
SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004086039	A2	20041007	WO 2004-IB1318	20040329
WO 2004086039	C1	20041104		
WO 2004086039	A3	20050113		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004235735	A1	20041125	US 2004-808735	20040325
CA 2520662	AA	20041007	CA 2004-2520662	20040329
EP 1613958	A2	20060111	EP 2004-724084	20040329

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

PRAI US 2003-457572P	P	20030327		
WO 2004-IB1318	W	20040329		

AB The invention discloses a method for modulating Nod1 activity which comprises providing cells expressing a functional Nod1 and bringing the cells into contact with a mol. related to MTP. The invention also discusses the use of a mol. related to MTP for modulating inflammation and /or apoptosis. The invention further discloses the methods for e.g. detection of peptidoglycan from a Gram-neg. bacteria in a sample.

L3 ANSWER 3 OF 4 USPATFULL on STN
AN 2004:299866 USPATFULL
TI Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof
IN Girardin, Stephen, Vincennes, FRANCE
Philpott, Dana, Vincennes, FRANCE
Sansonetti, Philippe, Paris, FRANCE
Boneca, Ivo, Vltry Sur Seine, FRANCE

PI	US 2004235735	A1	20041125
AI	US 2004-808735	A1	20040325 (10)
PRAI	US 2003-457572P		20030327 (60)

DT Utility
FS APPLICATION
LREP Finnegan Henderson Farabow Garrett & Dunner, Suite 700, 1300 I Street, N.W., Washington, DC, 20005
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 26 Drawing Page(s)
LN.CNT 1355
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for modulating Nod 1 activity wherein said method comprises the steps of providing cells expressing a functional Nod 1; and bringing said cells into contact with a molecule related to compositions comprising a molecule related to MTP and use of a molecule related to MTP for modulating inflammation and/or apoptosis

L3 ANSWER 4 OF 4 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
AN 2005:322248 BIOSIS
DN PREV200510112030
TI Host recognition of peptidoglycan by intracellular receptor Nod1 and Nod2, investigation with synthetic partial structures.
AU Kawasaki, Akiko [Reprint Author]; Inamura, Seiichi; Shimoyama, Atsushi; Inohara, Naohiro; Nunez, Gabriel; Fujimoto, Yukari; Fukase, Koichi; Kusumoto, Shoichi
CS Osaka Univ, Grad Sch Sci, Dept Chem, Osaka 5600043, Japan
SO Glycobiology, (NOV 2004) Vol. 14, No. 11, pp. 1199-1200.
Meeting Info.: Joint Meeting of the Society-for-Glycobiology/Japanese-Society-for-Carbohydrate-Research. Honolulu, HI, USA. November 17 -20, 2004. Soc Gylcobiol; Japanese Soc Carbohydrate Res.
ISSN: 0959-6658.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 25 Aug 2005
Last Updated on STN: 25 Aug 2005

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	42.76	47.24
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.75	-0.75

FILE 'REGISTRY' ENTERED AT 14:59:49 ON 16 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 FEB 2006 HIGHEST RN 874270-88-9
DICTIONARY FILE UPDATES: 14 FEB 2006 HIGHEST RN 874270-88-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *

```
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                  *
********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s l-ala-d-glu-mesoDAP
       1996569 L
         33843 ALA
       7840875 D
         26646 GLU
             0 MESODAP
L4           0 L-ALA-D-GLU-MESODAP
                 (L(W)ALA(W)D(W)GLU(W)MESODAP)

=> s dap
L5         248 DAP

=> s ala
L6       33843 ALA

=> s glu
L7       26646 GLU

=> s l6 (2w) l7 (2w) l5
L8           0 L6 (2W) L7 (2W) L5

=> d his

     (FILE 'HOME' ENTERED AT 14:54:01 ON 16 FEB 2006)

     INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
     AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
     CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
     DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 14:54:10 ON 16 FEB 2006
               SEA MURAMYL TRIPEPTIDE
              ---------
              51   FILE ADISCTI
               1   FILE ADISINSIGHT
               2   FILE ADISNEWS
               2   FILE AGRICOLA
               1   FILE ANABSTR
              14   FILE BIOENG
             223   FILE BIOSIS
               6   FILE BIOTECHABS
               6   FILE BIOTECHDS
              90   FILE BIOTECHNO
              17   FILE CABA
             183   FILE CAPLUS
               3   FILE CIN
               9   FILE CONFSCI
               2   FILE DDFB
             159   FILE DDFU
               1   FILE DGENE
               5   FILE DISSABS
               2   FILE DRUGB
             173   FILE DRUGU
             220   FILE EMBASE
              38   FILE ESBIOBASE
              25   FILE IFIPAT
               5   FILE IMSDRUGNEWS
               5   FILE IMSRESEARCH
               3   FILE JICST-EPLUS
              59   FILE LIFESCI
             219   FILE MEDLINE
               8   FILE NTIS
              99   FILE PASCAL
               3   FILE PHAR
               1   FILE PHARMAML
              12   FILE PHIN
              44   FILE PROMT
               1   FILE PROUSDDR
             208   FILE SCISEARCH
               1   FILE SYNTHLINE
             213   FILE TOXCENTER
             375   FILE USPATFULL
              37   FILE USPAT2
              29   FILE VETU
               1   FILE WATER
              20   FILE WPIDS
              20   FILE WPINDEX
L1             QUE MURAMYL TRIPEPTIDE
               ---------

     FILE 'USPATFULL, BIOSIS, EMBASE, MEDLINE, TOXCENTER, SCISEARCH, CAPLUS,
     DRUGU, PASCAL, BIOTECHNO, LIFESCI, ADISCTI, PROMT, ESBIOBASE, USPAT2,
     VETU, IFIPAT, WPIDS, CABA, BIOENG' ENTERED AT 14:58:08 ON 16 FEB 2006
L2             9 S L1 (P) (NOD1 OR CARD4)
L3             4 DUP REM L2 (5 DUPLICATES REMOVED)

     FILE 'REGISTRY' ENTERED AT 14:59:49 ON 16 FEB 2006
L4             0 S L-ALA-D-GLU-MESODAP
L5           248 S DAP
L6         33843 S ALA
L7         26646 S GLU
L8             0 S L6 (2W) L7 (2W) L5

=> log h
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    39.40      86.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -0.75
```

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 15:01:24 ON 16 FEB 2006